A 44-amino-acid GHRH analog stabilized by trans-3-hexenoic acid modification at the N-terminus, conferring resistance to enzymatic cleavage while preserving full GHRH receptor binding. Tesamorelin (trade name Egrifta) is FDA-approved for HIV-associated lipodystrophy — the only GHRH analog with active FDA marketing authorization. Unlike truncated GHRH analogs (Sermorelin, CJC-1295), tesamorelin retains all 44 native residues.
StabilityUse immediately after reconstitution (manufacturer guidance)
Key distinction: Only GHRH analog with current FDA approval — the full 44-residue structure with N-terminal stabilization provides the most complete GHRH receptor agonism available.
Scientific Evidence
Published Research
[1]
Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. NEJM 2007;357:2359-2370 — PubMed 18057338
[2]
Stanley TL et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. JAMA 2014;312:380-389 — PubMed 25038357
Research Use Only. All products sold by Lumen Peppers are intended solely for in vitro research and laboratory purposes. They are not drugs, supplements, or foods. Nothing on this page constitutes medical advice. Researchers are responsible for compliance with all applicable regulations. Last updated: April 14, 2026.